Equities Analysts Set Expectations for Amicus Therapeutics, Inc.’s FY2021 Earnings (NASDAQ:FOLD)

Equities Analysts Set Expectations for Amicus Therapeutics, Inc.’s FY2021 Earnings (NASDAQ:FOLD)

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Equities research analysts at Svb Leerink issued their FY2021 earnings per share estimates for shares of Amicus Therapeutics in a report released on Thursday, January 23rd. Svb Leerink analyst J. Schwartz anticipates that the biopharmaceutical company will post earnings per share of ($0.68) for the year.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Monday, November 11th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.08. The firm had revenue of $48.80 million during the quarter, compared to analyst estimates of $48.05 million. Amicus Therapeutics had a negative return on equity of 62.61% and a negative net margin of 216.02%. The business’s quarterly revenue was up 136.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.84) earnings per share.

FOLD has been the subject of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Amicus Therapeutics in a research report on Thursday, January 9th. ValuEngine upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 7th. BidaskClub lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Robert W. Baird reiterated a “buy” rating and issued a $20.00 price target on shares of Amicus Therapeutics in a research report on Thursday, January 9th. Finally, Zacks Investment Research upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 price target for the company in a research report on Monday, November 4th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Amicus Therapeutics has a consensus rating of “Buy” and an average price target of $18.86.

FOLD opened at $8.88 on Monday. The firm has a market cap of $2.28 billion, a P/E ratio of -5.65 and a beta of 1.55. Amicus Therapeutics has a 12 month low of $7.11 and a 12 month high of $14.61. The company has a current ratio of 6.20, a quick ratio of 6.10 and a debt-to-equity ratio of 0.36. The stock has a 50-day moving average of $9.67 and a 200 day moving average of $9.85.

In other Amicus Therapeutics news, CEO John F. Crowley sold 20,000 shares of the firm’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $9.02, for a total value of $180,400.00. Following the completion of the sale, the chief executive officer now owns 755,694 shares of the company’s stock, valued at $6,816,359.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Ellen Rosenberg sold 22,100 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $10.35, for a total transaction of $228,735.00. Following the completion of the sale, the insider now directly owns 185,350 shares of the company’s stock, valued at approximately $1,918,372.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 323,380 shares of company stock valued at $3,228,478. 2.50% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in Amicus Therapeutics by 12.7% in the second quarter. Vanguard Group Inc. now owns 22,330,661 shares of the biopharmaceutical company’s stock worth $278,687,000 after purchasing an additional 2,510,118 shares during the last quarter. BlackRock Inc. raised its stake in shares of Amicus Therapeutics by 10.8% during the second quarter. BlackRock Inc. now owns 18,580,413 shares of the biopharmaceutical company’s stock valued at $231,885,000 after acquiring an additional 1,805,661 shares in the last quarter. State Street Corp raised its stake in shares of Amicus Therapeutics by 18.2% during the third quarter. State Street Corp now owns 11,581,181 shares of the biopharmaceutical company’s stock valued at $92,881,000 after acquiring an additional 1,783,202 shares in the last quarter. Nuveen Asset Management LLC bought a new stake in shares of Amicus Therapeutics during the second quarter valued at approximately $36,848,000. Finally, Eagle Asset Management Inc. raised its stake in shares of Amicus Therapeutics by 1.9% during the third quarter. Eagle Asset Management Inc. now owns 2,768,660 shares of the biopharmaceutical company’s stock valued at $22,204,000 after acquiring an additional 51,260 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Share:
Scroll Up
error: Content is protected !!